$0.17 EPS Expected for AngioDynamics, Inc. (ANGO)

September 14, 2018 - By Robert Shackelford

AngioDynamics, Inc. (NASDAQ:ANGO) LogoInvestors sentiment increased to 1.5 in 2018 Q2. Its up 0.04, from 1.46 in 2018Q1. It is positive, as 10 investors sold AngioDynamics, Inc. shares while 44 reduced holdings. 29 funds opened positions while 52 raised stakes. 35.30 million shares or 1.16% more from 34.89 million shares in 2018Q1 were reported.
Minnesota-based Ameriprise has invested 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). Prudential Fincl stated it has 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). Geode Capital Mgmt Ltd Company reported 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Brinker holds 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO) or 12,574 shares. California Pub Employees Retirement Sys holds 0% or 150,965 shares. Alliancebernstein L P accumulated 0% or 142,540 shares. State Board Of Administration Of Florida Retirement Sys reported 0% stake. 535,883 were reported by Savings Bank Of Mellon. 37,950 are held by Perkins. Ameritas Inv Incorporated has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Royal Natl Bank Of Canada stated it has 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Rothschild Asset Mngmt Inc accumulated 97,729 shares. California State Teachers Retirement holds 55,769 shares. Financial Bank Of Montreal Can stated it has 56,361 shares or 0% of all its holdings. Ubs Asset Management Americas holds 20,338 shares.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.17 EPS on September, 27.They anticipate $0.05 EPS change or 41.67 % from last quarter’s $0.12 EPS. ANGO’s profit would be $6.30 million giving it 35.25 P/E if the $0.17 EPS is correct. After having $0.20 EPS previously, AngioDynamics, Inc.’s analysts see -15.00 % EPS growth. The stock decreased 0.08% or $0.02 during the last trading session, reaching $23.97. About 13,949 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 30.51% since September 14, 2017 and is uptrending. It has outperformed by 14.89% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 2 analysts covering Angiodynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Angiodynamics had 3 analyst reports since March 29, 2018 according to SRatingsIntel. Raymond James upgraded AngioDynamics, Inc. (NASDAQ:ANGO) on Tuesday, April 3 to “Outperform” rating. The company was maintained on Thursday, March 29 by Canaccord Genuity. The rating was maintained by Canaccord Genuity on Monday, April 2 with “Hold”.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $888.70 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 54.48 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More news for AngioDynamics, Inc. (NASDAQ:ANGO) were recently published by: Bizjournals.com, which released: “AngioDynamics expands oncology business with acquisition of Houston co.” on September 14, 2018. Seekingalpha.com‘s article titled: “AngioDynamics to acquire RadiaDyne” and published on September 13, 2018 is yet another important article.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.